Prosecution Insights
Last updated: April 19, 2026
Application No. 18/014,888

EXTERIORLY MOUNTED TISSUE ON EXPANDABLE FRAME FOR IMPROVED HEMODYNAMIC PERFORMANCE

Non-Final OA §102§103
Filed
Jan 06, 2023
Examiner
HU, ANN M
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Anteris Technologies Corporation
OA Round
3 (Non-Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
3y 10m
To Grant
89%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
631 granted / 932 resolved
-2.3% vs TC avg
Strong +21% interview lift
Without
With
+20.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
55 currently pending
Career history
987
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
43.8%
+3.8% vs TC avg
§102
30.5%
-9.5% vs TC avg
§112
17.9%
-22.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 932 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/18/2025 has been entered. Drawings The amendments to the drawings filed on 11/18/2025 are accepted. Response to Arguments Applicant’s arguments with respect to claim(s) 1 and 7-17 have been considered, but are moot in view of the new grounds of rejection. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tuval et al. (Pub. No.: US 2010/0262231 A1; hereinafter “Tuval”). Tuval discloses the following regarding claim 1: a heart valve prosthesis for transcatheter implantation at a native heart valve, the heart valve prosthesis comprising: a frame (12) having a distal end portion (Figs. 1, 2B) and a proximal end portion (Figs. 1, 2B), the frame further comprising an exterior surface (outer surface) (Figs. 1, 2B) and an interior surface (inner surface) (Figs. 1, 2B) defining a lumen (central opening of element 12), the frame expandable from an unexpanded state to an expanded state (paras. 0011, 0060-0061), wherein the frame further comprises: an expandable region near the distal end portion of the frame (para. 0041); and a cusp region (upper portions of element 12) near the proximal end portion of the frame (Figs. 1, 2B) and comprising a plurality of commissural posts (20, 30); and a valve construct (104) comprising: (i) a plurality of leaflets (Fig. 1; para. 0581-0582) and (ii) a plurality of commissural regions (130) that are monolithic with adjacent leaflets of the plurality of leaflets (para. 0582), the plurality of commissural regions defining a plurality of slits (open slits near element 130) through the valve construct (Fig. 4A), wherein each commissural post extends into the valve construct through a slit of one of the commissural regions so that portions of the valve construct are attached to the exterior surface of the frame at least at the plurality of commissural posts (Fig. 4A; paras. 0596-0597), and wherein one or more sutures (132) extend, in a commissure suture pattern (Fig. 4A), over each of the portions of the valve construct that are attached to the exterior surface of the frame (Fig. 4A) to attach the valve construct to the proximal end portion of the frame (Fig. 4A; paras. 0596-0597). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 7-10 and 12-17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tuval in view of Peterson et al. (Pub. No.: US 2021/0275298 A1; hereinafter “Peterson”). Tuval discloses the limitations of the claimed invention, as described above. Tuval does not disclose the use and position of radiopaque markers to allow for the use of the fluoroscopy techniques. Peterson teaches that it is well known in the art that radiopaque markers are applied to a frame having struts (Figs. 31-38E; paras. 0196-0201, 0222-0237, 0254-0267), for the purpose of aiding the user in the proper placement of the valve prosthesis and providing additional structural support to the prosthetic valve. The one or more radiopaque markers are located on one or more struts of the frame (Figs. 31-38E). The one or more radiopaque markers are located on at least one node of the frame where struts of adjacent cells of the frame are connected to each other (Figs. 38A-38E). The one or more radiopaque markers are also located on one or more struts of the frame (Figs. 31-38E). The one or more radiopaque markers are located on a distal row of struts of the distal end portion of the frame (Figs. 38D-38E). The one or more radiopaque markers (e.g., 3870) located on at least one commissural post (e.g., 3826) of the plurality of commissural posts (Figs. 38A-38B). The one or more radiopaque markers are located on a strut or node of the cusp region (Figs. 30-38E). The one or more radiopaque markers are located at or near a node of a distal-most row of cells of the frame (Figs. 38A-38E) to assist a practitioner in visualizing a position of a distal end of the distal end portion of the frame during delivery. The one or more radiopaque markers are located at or near a node of a proximal-most row of cells of the distal end portion of the frame (Figs. 38B-38C) to assist a practitioner in visualizing positions of the plurality of leaflets during delivery. The one or more radiopaque markers are located on a strut or node of the cusp region (Figs. 30-38E) to assist a practitioner in visualizing positions of the plurality of leaflets during delivery. It would have obvious to one having ordinary skill in the art to modify the device of Tuval to comprise a frame with struts having radiopaque markers, as taught by Peterson, in order to aid the user in the proper placement of the valve prosthesis and to provide additional structural support to the prosthetic valve. Such a modification would be made with a reasonable expectation of success. Please note that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. Claim(s) 11 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tuval in view of Dave et al. (Pub. No.: US 2008/0102098 A1; hereinafter “Dave”). Tuval discloses the limitations of the claimed invention, as described above. Tuval does not explicitly describe using a coating for the radiopaque markers on the frame. Dave teaches that it is well known in the art that radiopaque markers comprise a coating applied to the frame (paras. 0068-0069), for the purpose of aiding the user in the proper placement of the valve prosthesis. It would have obvious to one having ordinary skill in the art to modify the device of Tuval to comprise a radiopaque marker coating on its frame, as taught by Dave, in order to aid the user in the proper placement of the valve prosthesis. Such a modification would be made with a reasonable expectation of success. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Hu whose telephone number is (571) 272-6652. The examiner can normally be reached on Monday-Friday (9:00 am-5:30 pm EST). If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner’s supervisor, Jerrah Edwards, at (408) 918-7557. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANN HU/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Jan 06, 2023
Application Filed
Sep 03, 2024
Response after Non-Final Action
Aug 09, 2025
Non-Final Rejection — §102, §103
Aug 18, 2025
Response Filed
Oct 14, 2025
Final Rejection — §102, §103
Nov 18, 2025
Request for Continued Examination
Nov 22, 2025
Response after Non-Final Action
Jan 21, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12551339
EXPANDABLE IMPLANTABLE CONDUIT
2y 5m to grant Granted Feb 17, 2026
Patent 12533249
ACUTE AND CHRONIC DEVICES FOR MODIFYING FLOW IN BODY LUMENS AND METHODS OF USE THEREOF
2y 5m to grant Granted Jan 27, 2026
Patent 12521241
TRANSCATHETER VALVE PROSTHESIS HAVING AN EXTERNAL SKIRT FOR SEALING AND PREVENTING PARAVALVULAR LEAKAGE
2y 5m to grant Granted Jan 13, 2026
Patent 12514701
Low Profile Expandable Heart Valve
2y 5m to grant Granted Jan 06, 2026
Patent 12502273
PERIVALVULAR SEALING FOR TRANSCATHETER HEART VALVE
2y 5m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
89%
With Interview (+20.9%)
3y 10m
Median Time to Grant
High
PTA Risk
Based on 932 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month